Skip to content


  • Meeting abstracts
  • Open Access

HIV-associated primary lung cancer (LC) in the era of highly active antiretroviral therapy (HAART): a multi-institutional collaboration

  • 1,
  • 2,
  • 3,
  • 4, 5,
  • 5, 6,
  • 7,
  • 8, 9,
  • 10,
  • 10,
  • 11,
  • 12 and
  • 1, 5Email author
Infectious Agents and Cancer20105 (Suppl 1) :A32

  • Published:


  • Lung Cancer
  • Immune Reconstitution
  • Primary Lung Cancer
  • Cigarette Consumption
  • Lung Cancer Treatment


HIV-infected individuals are at increased risk for primary LC. We wished to compare the clinico-pathologic features and treatment outcome of HIV-LC patients with HIV-negative LC patients. We also sought to compare smoking habits and immunologic features of HIV-LC patients with HIV-positive patients without LC.


A database of 75 HIV-positive patients with primary LC in the HAART era was established from an international collaboration. These cases were drawn from the archives of contributing physicians who subspecialize in HIV malignancies. Patient characteristics were compared with registry data from the Surveillance Epidemiology and End Results (SEER, n=169,091 participants) Program and with HIV-positive individuals without LC from the Adult and Adolescent Spectrum of HIV-related Diseases (ASD, n=36,569 participants) Project.


The median age at HIV-related LC diagnosis was 50 years compared to 68 years for SEER participants (p<0.001). HIV-LC patients, like their SEER counterparts, most frequently presented with stage III (29% vs. 32%) and stage IV (55% vs. 48%) cancers, usually with adenocarcinoma (41% vs. 37%) or squamous carcinoma (32% vs. 20%) histologies. HIV-LC patients and ASD participants had comparable median nadir CD4+ cell counts (138 vs. 160 cells/μL). HIV-LC patients were, however, more likely to be smokers (99% vs. 76%; p<0.001) with a higher median pack-year history of cigarette consumption (41 vs. 14 pack-years; p<0.001). At LC diagnosis, their median CD4+ count was 340 cells/μL and 86% were receiving HAART. Sixty-three (84%) HIV-LC patients received cancer-specific treatments, but chemotherapy-associated toxicity was substantial. The median survival among HIV-LC patients and SEER participants both measured 9 months.


Smoking was tightly associated with the risk of HIV-LC. Most HIV patients were receiving HAART and had substantial immune reconstitution at time of LC diagnosis. They were able to receive LC treatments; their tumor types and overall survival were similar to SEER LC participants. However, HIV-LC patients were diagnosed with LC at a younger age than their HIV-negative counterparts. Future research should explore how screening and diagnostic and treatment strategies directed toward the general population may apply to HIV-positive patients at risk for LC.



This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at

Authors’ Affiliations

Division of Hematology/Oncology, Virginia Mason Medical Center, Seattle, WA, USA
Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
Chelsea & Westminster Hospital, London, UK
Public Health-Seattle and King County, HIV/AIDS Epidemiology, Seattle, WA, USA
University of Washington, Seattle, WA, USA
ICON Clinical Research, San Francisco, CA, USA
School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA
Section of Hematology/Oncology, Boston Medical Center, Boston, MA, USA
Section of Hematology/Oncology, Boston University School of Medicine, Boston, MA, USA
Joan Karnell Cancer Center, Philadelphia, PA 19107, USA
Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Imperial College, Charing Cross Hospital, London, UK


© D'Jaen et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.